A RANDOMIZED, OPEN-LABEL, TWO-WAY CROSSOVER TRIAL TO DETERMINE THE PHARMACOKINETICS OF METOCLOPRAMIDE WHEN ADMINISTERED AS THE ORALLY DISINTEGRATING TABLET COMPARED TO REGLAN® TABLETS IN SUBJECTS WITH DIABETIC GASTROPARESIS: